Reuters logo
Rigel experimental eye drug fails mid-stage study
August 13, 2014 / 11:49 AM / 3 years ago

Rigel experimental eye drug fails mid-stage study

Aug 13 (Reuters) - Rigel Pharmaceuticals Inc said its experimental drug failed to meet the main goal in a mid-stage study in patients with dry eye disease.

The study was testing the drug, R348, against a placebo in the trial.

Rigel said it had decided not to initiate new studies of R348 for this indication, but was continuing a mid-stage study of the drug in dry eye patients with graft versus host disease.

The company also said it would stop testing another drug, codenamed R118, due to its side-effect profile in early-stage trials. (Reporting by Natalie Grover in Bangalore; Editing by Simon Jennings)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below